COMPLETED

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)

Official Title

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

Quick Facts

Study Start:2020-09-01

Study Completion:2026-01-22

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT04164212

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 49 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT

Inclusion Criteria	Exclusion Criteria
* ages 18-49 years old, * not yet received influenza vaccine for 2019-2020, and * capable of giving signed informed consent.	* Immunocompromising condition (e.g. HIV/AIDS, chemotherapy, immune suppressing medications), * active smoking within past 6 months, * asthma, chronic lung/liver/kidney /neurologic/hematologic/metabolic disorders,cardiovascular disease (excluding isolated hypertension), diabetes mellitus, disease, congestive heart failure, * pregnancy, * current or recent (within the past month) upper/lower respiratory tract infection, chronic sinusitis/nasal allergies requiring frequent or daily therapy (including topical corticosteroids), * prior adverse reaction to influenza vaccine, * history of Guillain-Barre syndrome, * egg allergy, * close contact with an individual with severe immunodeficiency/immunosuppression.

Inclusion Criteria

Exclusion Criteria

* ages 18-49 years old,
* not yet received influenza vaccine for 2019-2020, and
* capable of giving signed informed consent.

* Immunocompromising condition (e.g. HIV/AIDS, chemotherapy, immune suppressing medications),
* active smoking within past 6 months,
* asthma, chronic lung/liver/kidney /neurologic/hematologic/metabolic disorders,cardiovascular disease (excluding isolated hypertension), diabetes mellitus, disease, congestive heart failure,
* pregnancy,
* current or recent (within the past month) upper/lower respiratory tract infection, chronic sinusitis/nasal allergies requiring frequent or daily therapy (including topical corticosteroids),
* prior adverse reaction to influenza vaccine,
* history of Guillain-Barre syndrome,
* egg allergy,
* close contact with an individual with severe immunodeficiency/immunosuppression.

Contacts and Locations

Study Locations (Sites)

UAB Lung Health Center

Birmingham, Alabama, 35233

United States

Collaborators and Investigators

Sponsor: University of Alabama at Birmingham

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2020-09-01

Study Completion Date2026-01-22

Study Record Updates

Study Start Date2020-09-01

Study Completion Date2026-01-22

Terms related to this study

Additional Relevant MeSH Terms

Influenza